By Jill Stein Special to DG News NEW YORK, NY — May 16, 2002 —
The fixed-dose combination of amlodipine/benazepril decreases blood pressure earlier and to a greater extent than the angiotensin-converting enzyme (ACE) inhibitor enalapril given alone in patients with hypertension and type 2 diabetes, researchers reported at the 17th Annual Scientific Meeting of the American Society of Hypertension (ASH).
The results also show that amlodipine/benazepril achieved its effect with no sacrifice in renal protection caused by the addition of the calcium channel blocker. Dr. George Bakris, of Rush Presbyterian/St. Luke’s Medical Center in Chicago, Illinois, and associates randomised 214 patients to enalapril (10 mg titrated to 20 mg) or the fixed dose combination of amlodipine/benazepril (5 mg/10 mg titrated to 5 mg/20 mg). Hydrochlorothiazide, 12.5 mg, was added if patients had not reached their target blood pressure level at eight weeks.
The primary end point was the time to goal of blood pressure less than 130/85 mm Hg. The study found that subjects taking the fixed-dose combination of amlodipine/benazepril achieved their target blood pressure significantly faster than did subjects who received ACE inhibitor monotherapy (5.3 weeks versus 6.4 weeks, respectively).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!